AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety
Conditions
Safety, Tolerability, Pharmacokinetics, Healthy Subjects
Trial Timeline
Jul 1, 2015 → Nov 1, 2015
NCT ID
NCT02484729About AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution
AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is completed. This product is registered under clinical trial identifier NCT02484729. Target conditions include Safety, Tolerability, Pharmacokinetics.
What happened to similar drugs?
3 of 4 similar drugs in Safety were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02484729 | Phase 1 | Completed |
Competing Products
20 competing products in Safety